Posted by Michael Wonder on 04 Aug 2022
Vaxcyte provides positive regulatory updates for VAX-24 adult and paediatric programs
4 August 2022 - Company receives FDA fast track designation for VAX-24 in adults.
Vaxcyte today announced that the U.S. FDA has granted fast track designation to VAX-24, the Company’s 24 valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease, in adults ages 18 and older.
